Type 2 Diabetes Mellitus: A Global Challenge and Solutions
Type 2 diabetes mellitus (T2DM) is one of the most widespread modern pandemics, affecting millions of people worldwide and posing a serious threat to public health [1, 2]. According to World Health Organization (WHO) projections, diabetes could become the seventh leading cause of death by 2030 [2]. This disease is frequently accompanied by chronic kidney disease (CKD), which significantly increases the risk of cardiovascular complications and the need for dialysis or kidney transplantation [1].
Despite significant advancements in the development of antidiabetic drugs and the availability of multiple FDA-approved therapeutic options, many patients fail to achieve adequate glycemic control [2]. This highlights the need for a comprehensive, personalized treatment approach that considers not only glucose levels but also comorbid conditions such as cardiovascular pathology and CKD [1, 3].
A Comprehensive Approach to Type 2 Diabetes Treatment
Effective management of T2DM requires a multifaceted approach based on the latest scientific evidence and clinical guidelines. The American Association of Clinical Endocrinology (AACE) regularly updates its algorithms for the diagnosis and management of adults with T2DM, offering evidence-based graphical guides for healthcare professionals [3]. These recommendations emphasize the importance of shared decision-making with the patient to improve treatment outcomes [3].
Key principles of comprehensive treatment include:
- Effective antihyperglycemic control [1].
- Blood pressure management [1].
- Correction of dyslipidemia [3].
- Consideration of comorbid conditions and complications [3].
The Polish Society of Nephrology, for instance, highlights five main directions of nephroprotective pharmacotherapy in patients with CKD and T2DM: effective antihyperglycemic treatment, the use of SGLT2 inhibitors or semaglutide, antihypertensive therapy, the use of RAAS inhibitors (ARBs or ACE inhibitors), and, in certain patients, finerenone, as well as sodium bicarbonate for metabolic acidosis [1].
SGLT2 Inhibitors: Heart and Kidney Protection
Sodium-glucose cotransporter-2 (SGLT2) inhibitors have become a breakthrough in the treatment of T2DM, demonstrating significant benefits that extend far beyond simply lowering glucose levels. These drugs improve cardiorenal outcomes in patients with T2DM, chronic kidney disease, and chronic heart failure [4].
Key benefits of SGLT2 inhibitors:
- Reduction in the risk of cardiovascular mortality [4].
- Decrease in the frequency of heart failure hospitalizations, even in patients with T2DM and a history of myocardial infarction (MI) [4].
- Serving as a key component of nephroprotective pharmacotherapy in patients with CKD and T2DM, slowing the progression of kidney disease [1].
Currently, the potential of early SGLT2 inhibitor use in patients with acute myocardial infarction is actively being investigated to improve outcomes [4].
GLP-1 Receptor Agonists: Glycemic and Weight Control
Glucagon-like peptide-1 (GLP-1) receptor agonists represent another important class of medications widely used in the treatment of T2DM. They are known for their efficacy in glycemic control and weight management, which is particularly relevant given that obesity frequently accompanies T2DM [6].
The use of GLP-1 receptor agonists is growing, generating interest in their potential impact on thyroid function. Thyroid dysfunction is common in metabolic conditions such as diabetes and obesity, pointing to a deep interconnection between these systems. However, despite various studies, current data on the effects of GLP-1 agonists on thyroid function remain inconclusive and contradictory [6].
Other Important Aspects of Pharmacotherapy
Aside from SGLT2 inhibitors and GLP-1 agonists, other drug classes and strategies are critical for the comprehensive management of T2DM, especially in the presence of complications:
- Antihypertensive therapy: Blood pressure control is an integral part of nephroprotection and cardiovascular risk reduction in patients with T2DM and CKD [1].
- Renin-angiotensin-aldosterone system (RAAS) inhibitors: The use of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme (ACE) inhibitors is a cornerstone of renal protection in patients with T2DM and CKD [1].
- Finerenone: In certain patients with CKD and T2DM, the use of finerenone, a non-steroidal mineralocorticoid receptor antagonist, may be indicated for additional nephroprotection [1].
- Sodium bicarbonate: In the presence of metabolic acidosis in patients with CKD and T2DM, sodium bicarbonate may be used to correct acid-base balance [1].
These approaches aim to target multiple pathways in the development of T2DM complications, providing comprehensive protection of target organs [1].
Why Is Achieving Target Metrics Important?
Despite an abundance of therapeutic options, many patients fail to achieve adequate glycemic control, leading to disease progression and the development of serious complications [2]. Uncontrolled T2DM is associated with an increased risk of cardiovascular disease and the progression of CKD to stages requiring dialysis or transplantation [1].
Furthermore, T2DM impacts the lungs, contributing to inflammation, increased risk of exacerbations, and the severity of obstructive airway diseases such as asthma and chronic obstructive pulmonary disease (COPD) [7]. The use of corticosteroids for respiratory diseases, in turn, can exacerbate metabolic disorders [7].
Special attention is paid to the rising prevalence of diabetes in children, where early detection and treatment optimization are essential to achieve glycemic control, limit weight gain, and improve quality of life [8]. The continuous development of new therapeutic options with multiple mechanisms of action and improved efficacy is critically important for overcoming the challenges associated with T2DM [2].
Sources
- [1] Pharmacological Nephroprotection in Chronic Kidney Disease Patients with Type 2 Diabetes Mellitus-Clinical Practice Position Statement of the Polish Society of Nephrology. (International Journal of Molecular Sciences, 2024) https://pubmed.ncbi.nlm.nih.gov/39684653/
- [2] Treatment Avenues for Type 2 Diabetes and Current Perspectives on Adipokines. (Current Diabetes Reviews, 2018) https://pubmed.ncbi.nlm.nih.gov/28081698/
- [3] American Association of Clinical Endocrinology Consensus Statement: Algorithm for Management of Adults With Type 2 Diabetes - 2026 Update. (Endocrine Practice: Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2026) https://pubmed.ncbi.nlm.nih.gov/41842862/
- [4] Sodium Glucose Cotransporter-2 Inhibition for Acute Myocardial Infarction: JACC Review Topic of the Week. (Journal of the American College of Cardiology, 2022) https://pubmed.ncbi.nlm.nih.gov/35589167/
- [6] Implications of GLP-1 Receptor Agonist on Thyroid Function: A Literature Review of Its Effects on Thyroid Volume, Risk of Cancer, Functionality and TSH Levels. (Biomolecules, 2024) https://pubmed.ncbi.nlm.nih.gov/38927090/
- [7] Type 2 Diabetes and the Lung - Cause and Consequence. (Current Diabetes Reports, 2026) https://pubmed.ncbi.nlm.nih.gov/42095998/
- [8] The changing face of paediatric diabetes. (Diabetologia, 2020) https://pubmed.ncbi.nlm.nih.gov/31897525/
The information provided in this article is for reference purposes only and should not be used for self-diagnosis or self-treatment. Always consult a qualified medical professional for an accurate diagnosis and individualized treatment plan.